Eli Lilly's Q1 revenue soared by 45% to $12.73 billion, thanks to strong sales of Mounjaro and Zepbound. The company also reported a 23% increase in net income to $2.76 billion and...
Eli Lilly's first quarter revenue jumps 45% to $12.73 billion, driven by Mounjaro and Zepbound. Net income rises 23% to $2.76 billion, with EPS at $3.06. Plans for a $50 billion US...
Eli Lilly's first-quarter revenue for fiscal 2025 soared by 45% to $12.73 billion, thanks to the strong performance of Mounjaro and Zepbound. The company also reported a 23% increa...
Eli Lilly's Q1 revenue jumps 45% to $12.7 billion, fueled by Mounjaro and Zepbound. Net income up 23% to $2.76 billion, with EPS at $3.06. Plans for $50 billion US manufacturing ex...
Eli Lilly's Q1 revenue surged by 45% to $12.73 billion, thanks to strong sales of Mounjaro and Zepbound. The company also reported a net income increase of 23% and announced a $50 ...
Eli Lilly reports a 45% revenue surge to $12.73 billion in Q1 2025, driven by Mounjaro and Zepbound. Net income rose by 23% to $2.76 billion, with EPS at $3.06. CEO highlights forg...
Eli Lilly's first-quarter revenue jumps 45% to $12.73 billion, fueled by Mounjaro and Zepbound sales. Net income rises 23% to $2.76 billion, with EPS at $3.06. CEO David Ricks high...
Eli Lilly and Company forecasts a significant revenue increase to $58-61 billion by 2025, driven by strong sales of its diabetes and obesity treatments, Mounjaro and Zepbound. CEO ...
